Point72 Asset Management
TVTX icon

Point72 Asset Management’s Travere Therapeutics TVTX Stock Holding History

Point72 Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,100
Closed -$462K – 4528
2025
Q4 		$462K Buy
+12,100
New +$393K ﹤0.01% 3274

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management's TVTX Position: Q1 2026 in Review

Point72 Asset Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 173,383 shares — an estimated $6.62M sold.

Point72 Asset Management first reported a position in TVTX in Q2 2015 and held it in 28 quarters. The position peaked at $40.2M in Q1 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Point72 Asset Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 173,383 Travere Therapeutics shares in Q1 2026, an estimated $6.62M.
  • Point72 Asset Management first reported a position in Travere Therapeutics in Q2 2015 and held it in 28 quarters.
  • Point72 Asset Management's Travere Therapeutics position peaked at $40.2M in Q1 2021.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.